ICER Priced Tavapadon Before the FDA Approved It or AbbVie Named a Price
- The Institute for Clinical and Economic Review posted a revised Evidence Report on 16 September 2026 assessing AbbVie‘s tavapadon in Parkinson’s disease, concluding it is comparable to currently available treatments and not cost effective against key alternatives. Tavapadon has not been approved by the FDA and no US price has been announced.
- For Parkinson’s with motor fluctuations, tavapadon added to levodopa produced a health benefit price benchmark between $4,764 and $6,861 per year. For early Parkinson’s, ICER could not calculate a benchmark at all, citing significant uncertainty regarding the mix of benefits and harms.
- Against no pharmacological treatment, and as an add-on to levodopa, ICER rated tavapadon C++, meaning moderate certainty of a small to substantial net health benefit. Against four active comparator classes, levodopa, dopamine agonists, COMT inhibitors and MAO-B inhibitors, it rated the evidence promising but inconclusive.
- Chief Scientific Officer Dan Ollendorf said benefits were similar to those of older generic drugs and that discontinuation due to adverse events was relatively high. The report goes to a public meeting of ICER’s California Technology Assessment Forum on 1 October 2026.
CI read
An assessment body has published a price range for a product that has neither an approval nor a price. The number will be in the room during every payer negotiation that follows launch.
- The benchmark arrives before the launch price, which reverses the usual order. A manufacturer normally sets a price and defends it. AbbVie will now announce a figure that gets read against $4,764 to $6,861 before anyone examines the clinical case. Anchoring of that kind is difficult to unwind.
- The inability to price early Parkinson’s is the harsher finding. ICER declining to calculate any benchmark, on uncertainty about the mix of benefits and harms, is a stronger statement than a low number. Of the 2 settings assessed, the one it could not value is where the larger population sits.
- Comparison against generics is the commercial problem. Ollendorf’s framing puts benefits alongside older generic drugs with relatively high discontinuation, and 4 active comparator classes returned promising but inconclusive ratings. A novel agent priced against levodopa and generic dopamine agonists needs a differentiation argument that this report does not supply.